NCT07205068

Brief Summary

The primary purpose of this study is to observe reduced access site complications in patients with heavily calcified common femoral arteries requiring Transcatheter Aortic Valve Replacement (TAVR)

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
6mo left

Started Oct 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress55%
Oct 2025Nov 2026

First Submitted

Initial submission to the registry

August 21, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 3, 2025

Completed
1 day until next milestone

Study Start

First participant enrolled

October 4, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 4, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 4, 2026

Last Updated

October 3, 2025

Status Verified

August 1, 2025

Enrollment Period

1.1 years

First QC Date

August 21, 2025

Last Update Submit

September 30, 2025

Conditions

Keywords

Aortic StenosisTranscatheter aortic valve replacement

Outcome Measures

Primary Outcomes (1)

  • Evaluate for contrast extravasation post closure of femoral artery at the end of the procedure

    Immediately post-procedure

Secondary Outcomes (15)

  • Determine need for Vascular surgery consultation

    During hospital stay (Day 0-3)

  • If vascular complication, was PTA, stenting, or open surgery used

    During hospital stay (Day 0-3)

  • Number of perclose devices used to close the femoral artery access site

    During procedure (Day 0)

  • Determine presence of other vascular complications I.e. bleeding, hematoma, emboli etc

    Within 3 days post-procedure

  • Change in Hemoglobin

    Day 0 to Day 3 post-procedure

  • +10 more secondary outcomes

Study Arms (2)

Shockwave model (M5) Intravascular Lithotripsy (IVL)

EXPERIMENTAL

Patients will be treated with the Shockwave M5 Intravascular Lithotripsy (IVL) device prior to femoral artery access using the modified Seldinger technique

Device: Shockwave M5 IVL CatheterProcedure: Modified Seldinger Technique

Standard femoral access

ACTIVE COMPARATOR

Patients will receive standard femoral artery access via the modified Seldinger approach without utilizing intravascular lithotripsy in heavily calcified femoral arteries

Procedure: Modified Seldinger Technique

Interventions

The Shockwave M5 IVL Catheter is a balloon catheter designed to modify calcified arterial plaque using intravascular lithotripsy prior to vascular access

Shockwave model (M5) Intravascular Lithotripsy (IVL)

Standard of care for femoral access in patients with calcified femoral arteries

Shockwave model (M5) Intravascular Lithotripsy (IVL)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \>18 years of age
  • Patient with a diagnosis of severe aortic stenosis undergoing TAVR
  • Participants must be able to read and understand study procedures
  • Willing to participate and sign an ICF
  • Patients with \> 90-degree arc of calcium at the large bore access site per CT documentation

You may not qualify if:

  • Unable to understand study procedures
  • Unwilling to give consent
  • Patients with cognitive impairments that can affect their ability to give consent
  • Unfavorable calcium distribution of femoral artery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Tennessee Medical Center

Knoxville, Tennessee, 37920, United States

RECRUITING

MeSH Terms

Conditions

Aortic Valve Stenosis

Condition Hierarchy (Ancestors)

Aortic Valve DiseaseHeart Valve DiseasesHeart DiseasesCardiovascular DiseasesVentricular Outflow Obstruction

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 21, 2025

First Posted

October 3, 2025

Study Start

October 4, 2025

Primary Completion (Estimated)

November 4, 2026

Study Completion (Estimated)

November 4, 2026

Last Updated

October 3, 2025

Record last verified: 2025-08

Locations